Sex differences in the clinical manifestation of autosomal dominant frontotemporal dementia
Molly Memel,Adam Staffaroni,Ignacio Ilan-Gala,Jesus Garcia Castro,John Kornak,Carmela Tartaglia,Rowan Saloner,Anna VandeBunte,Emily Paolillo,Claire Cadwallader,Coty Chen,Maria Luisa Gorno-Tempini,Malu Mandelli,Liana Apostolova,Neil Graff-Radford,Irene Litvan,Ece Bayram,Peter Pressman,Toji Miyagawa,Ian Mackenzie,Jill Goldman,Richard Darby,Brian Appleby,Len Petrucelli,Tania Gendron,Hilary Heuer,Leah Forseberg,Julio Rojas,Brad Boeve,Nellie Brushaber,Kimiko Domoto-Reilly,Nupur Ghoshal,Maria Lapid,Belen Pascual,Suzee Lee,Eilana Ramos,Vijay Ramanan,Rosa Rademakers,Katya Rascovsky,Alex Pantelyat,Joseph Masdeu,Allison Snyder,Adam Boxer,Howard Rosen,Kaitlin Casaletto
DOI: https://doi.org/10.1101/2024.10.01.614851
2024-10-03
Abstract:INTRODUCTION: Sex differences are apparent in neurodegenerative diseases, but have not been comprehensively characterized in frontotemporal dementia (FTD).
METHODS: Participants included 337 adults with autosomal dominant FTD enrolled in the ALLFTD Consortium. Clinical assessments and plasma were collected annually for up to six years. Linear mixed-effects models investigated how sex and disease stage associated with longitudinal trajectories of cognition, function, and neurofilament light chain (NfL).
RESULTS: While sex differences were not apparent at asymptomatic stages, females showed more rapid declines across all outcomes in symptomatic stages compared to males. In asymptomatic participants, the association between baseline NfL and clinical trajectories was weaker in females versus males, a difference that attenuated in symptomatic participants.
DISCUSSION: In genetic FTD, females show cognitive resilience in early disease stages followed by steeper clinical declines later in disease. Baseline NfL may be a less sensitive prognostic tool for clinical progression in females with FTD-causing mutations.
Neuroscience